Pulsed Electromagnetic Fields in Cancer Therapy: A Review of Experimental and Clinical Evidence

Pulsed electromagnetic fields (PEMF) are emerging as a non-invasive adjunct in cancer therapy. Initially approved for orthopedic applications such as bone healing and tissue regeneration, PEMF has demonstrated broader biological effects including modulation of inflammation, angiogenesis, cellular metabolism, and signal transduction. Increasing experimental and early clinical evidence suggests that specific electromagnetic field exposures may inhibit tumor cell proliferation, induce apoptosis, disrupt mitotic spindle formation, and impair angiogenesis across multiple cancer types. This review synthesizes findings from studies investigating low- and high-intensity PEMF, intermediate-frequency tumor-treating alternating electric fields, and tumor-specific amplitude-modulated radiofrequency electromagnetic fields (AM-RF EMF) in cancer cell lines, animal models, and preliminary human clinical trials. Across these modalities, therapeutic responses appear highly dependent on field strength, frequency, waveform, exposure duration, and tumor biology. While intermediate-frequency alternating electric fields selectively target dividing cells through mitotic disruption, AM-RF EMF protocols have demonstrated early clinical activity in hepatocellular carcinoma and other malignancies without significant toxicity. Low- and higher-intensity PEMF exposures have also shown antiproliferative and pro-apoptotic effects in diverse tumor models, often enhancing sensitivity to chemotherapy, radiation, and targeted therapies. Despite encouraging results, clinical translation remains limited due to mechanistic heterogeneity and the absence of standardized treatment protocols. To address these challenges, this review proposes a framework integrating cancer genomics, structural biology, and thermodynamic modeling to guide rational design of electromagnetic field therapies. By estimating the electromagnetic field strengths required to perturb protein–ligand interactions or disrupt key oncogenic signaling pathways, PEMF protocols may be tailored to individual tumor molecular profiles. Although current biophysical estimates remain preliminary, they provide a conceptual basis for hypothesis-driven optimization. Rigorous randomized clinical trials, mechanistic validation, and standardized exposure parameters will be essential to establish the role of PEMF as a precision, mechanism-informed component of multimodal cancer therapy.